164 related articles for article (PubMed ID: 27473285)
1. Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects.
Aiudi A; Miller B; Krishna G; Adedoyin A; Xiao A
Fundam Clin Pharmacol; 2016 Dec; 30(6):625-633. PubMed ID: 27473285
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
Monogue ML; Stainton SM; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
[TBL] [Abstract][Full Text] [Related]
3. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.
Wooley M; Miller B; Krishna G; Hershberger E; Chandorkar G
Antimicrob Agents Chemother; 2014; 58(4):2249-55. PubMed ID: 24492369
[TBL] [Abstract][Full Text] [Related]
4. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study.
Yu B; Adedoyin A; Hershberger E; Caro L; Xiao A; Rhee EG; Huntington JA
Clin Pharmacol Drug Dev; 2018 May; 7(4):382-391. PubMed ID: 29517862
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.
Miller B; Hershberger E; Benziger D; Trinh M; Friedland I
Antimicrob Agents Chemother; 2012 Jun; 56(6):3086-91. PubMed ID: 22450972
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
[TBL] [Abstract][Full Text] [Related]
8. A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participants.
Liu N; Wang X; Zhu J; Basu S; Wei Y; Yan B; Wang H; Colon-Gonzalez F; Feng HP; Sun F; Li H; Zang Y
Int J Antimicrob Agents; 2023 Mar; 61(3):106717. PubMed ID: 36640850
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
Bradley JS; Ang JY; Arrieta AC; Larson KB; Rizk ML; Caro L; Yang S; Yu B; Johnson MG; Rhee EG
Pediatr Infect Dis J; 2018 Nov; 37(11):1130-1136. PubMed ID: 30153232
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
Chandorkar G; Xiao A; Mouksassi MS; Hershberger E; Krishna G
J Clin Pharmacol; 2015 Feb; 55(2):230-9. PubMed ID: 25196976
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
[TBL] [Abstract][Full Text] [Related]
12. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
[TBL] [Abstract][Full Text] [Related]
13. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Melchers MJ; Mavridou E; Seyedmousavi S; van Mil AC; Lagarde C; Mouton JW
Antimicrob Agents Chemother; 2015; 59(6):3373-6. PubMed ID: 25824214
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Xiao AJ; Miller BW; Huntington JA; Nicolau DP
J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
[TBL] [Abstract][Full Text] [Related]
16. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.
Ang JY; Arrieta A; Bradley JS; Zhang Z; Yu B; Rizk ML; Johnson MG; Rhee EG
Am J Perinatol; 2021 Jul; 38(8):804-809. PubMed ID: 31910460
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Roilides E; Ashouri N; Bradley JS; Johnson MG; Lonchar J; Su FH; Huntington JA; Popejoy MW; Bensaci M; De Anda C; Rhee EG; Bruno CJ
Pediatr Infect Dis J; 2023 Apr; 42(4):292-298. PubMed ID: 36689671
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Sucher AJ; Chahine EB; Cogan P; Fete M
Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
